Last reviewed · How we verify

Jiangsu HengRui Medicine Co., Ltd. — Portfolio Competitive Intelligence Brief

Jiangsu HengRui Medicine Co., Ltd. pipeline: 5 marketed, 0 filed, 60 Phase 3, 43 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

5 marketed 0 filed 60 Phase 3 43 Phase 2 111 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Imipenem and Cilastatin Sodium Imipenem and Cilastatin Sodium marketed Beta-lactam antibiotic (carbapenem) with dehydropeptidase inhibitor Penicillin-binding proteins (PBPs); bacterial cell wall peptidoglycan; renal dehydropeptidase I Infectious Disease
FOLFOX4 FOLFOX4 marketed Other
Remimazolam Tosilate for Injection Remimazolam Tosilate for Injection marketed Benzodiazepine GABA-A receptor Anesthesia/Sedation
ApatinibTablets ApatinibTablets marketed
Digoxin tablet Digoxin tablet marketed
Noiiglutide Injection Noiiglutide Injection phase 3 GLP-1 receptor agonist GLP-1R Diabetes
Pyrotinib in combination with Capecitabine. Pyrotinib in combination with Capecitabine. phase 3 Tyrosine kinase inhibitor HER2/neu Oncology
SHR-A1811 Injection ； Pertuzumab Injection SHR-A1811 Injection ； Pertuzumab Injection phase 3 HER2 inhibitor monoclonal antibody HER2 (human epidermal growth factor receptor 2) Oncology
SHR2554 analog tablets; Chidamide SHR2554 analog tablets; Chidamide phase 3 Histone deacetylase inhibitor Histone deacetylases Oncology
SHR8554 Injection SHR8554 Injection phase 3 GLP-1 receptor agonist GLP-1R Diabetes
Carboplatin for Injection Carboplatin for Injection phase 3 Platinum-based chemotherapy agent DNA Oncology
SHR7280 simulant； Ganirelix Acetate Injection SHR7280 simulant； Ganirelix Acetate Injection phase 3 GnRH antagonist GnRH receptor Reproductive Medicine / Fertility

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Pfizer · 14 shared drug classes
  2. AstraZeneca · 9 shared drug classes
  3. GlaxoSmithKline · 5 shared drug classes
  4. Merck Sharp & Dohme LLC · 5 shared drug classes
  5. Sun Yat-sen University · 5 shared drug classes
  6. Ahn-Gook Pharmaceuticals Co.,Ltd · 4 shared drug classes
  7. Eli Lilly and Company · 4 shared drug classes
  8. Akeso · 4 shared drug classes

Subscribe to ongoing alerts

Every new pipeline event for Jiangsu HengRui Medicine Co., Ltd.:

Cite this brief

Drug Landscape (2026). Jiangsu HengRui Medicine Co., Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/jiangsu-hengrui-medicine-co-ltd. Accessed 2026-05-17.

Related